This brief report compares and
B ased on a guideline template derived from the American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) 2007 HER2 Testing Guideline, the 2011 ASCO/CAP Estrogen Receptor (ER) and Progesterone Receptor (PR) Testing Guideline seeks to fulfill the same goals; the guidelines provide clarification about testing parameters for these breast predictive factor tests and establish mandatory proficiency testing and inspection criteria in order to improve the accuracy of these tests. [1] [2] [3] [4] [5] Such tests have high impact on patient care as results directly define the treatment that a patient will receive. 6 Hormonal treatments and HER2 receptor-based treatments have been found to be highly effective for breast cancer patients.
Recommendations in each guideline include definitions of positive and negative results. The ASCO/CAP ER PR guideline defines positive for each test as 1% of tumor cells showing nuclear staining with antibody directed against either ER or PR. This threshold is lower than that used by many pathologists. Patients with 1% to 10% staining for ER are uncommon, but there is evidence that patients with even low-level staining will respond to hormonal manipulation. 2 Patients with either newly diagnoses invasive cancer of the breast of any type or with newly diagnoses metastatic breast cancer should be tested for both ER and PR. In situ breast carcinoma can be tested, but there is insufficient evidence to recommend routine testing. PR testing is recommended in addition to ER testing because patients with ER-positive, PRnegative breast carcinoma have a worse prognosis than those with ER-positive and PR-positive tumors. [1] [2] [3] [4] Specimen handling considerations for ER and PR testing have become more tightly defined. In the ASCO/ CAP ER/PR guideline, it is mandatory to record the time of removal of tumors from patients and the time the tissue is grossly examined and placed in 10% neutral-buffered formalin. Breast cancer specimens obtained at locations remote from the grossing location must also have these times recorded. The specimen must at least be bisected through the tumor before transport, so that the total time from removal to fixation remains < 1 hour. [1] [2] [3] [4] [5] In the HER2-testing guideline, these intervals were recommended but not mandatory. Both the HER2 and ER/ PR guidelines recommend that samples be fixed in 10% neutral-buffered formalin for at least 6 hours. Cytology samples must also be fixed in formalin. HER2 guideline recommendation requires that samples not be fixed longer than 48 hours, because existing evidence at the time of publication did not provide evidence that longer fixation did not compromise accuracy of testing. 5 For ER testing, fixation intervals of up to 72 hours are permissible, based on existing evidence.
In the ASCO/CAP HER2 guideline, Federal Drug Administration approved reagent kits were available including well characterized antibodies for immunohistochemistry and probes for fluorescence in situ hybridization. The guideline recommended use of these kits and antibodies. 1 The situation is different with ER and PR testing. A larger number of antibodies is available and have been used in various non-Federal Drug Administration approved protocols since the mid 1990s. The ASCO/CAP ER PR Guideline specifies acceptable antibodies in a different way for this document. Antibodies which are acceptable for use in ER and PR testing are only those where the clinical validity of the antibody method has been established and published. 2, 3, 7 The guideline document provides a list of those antibodies, which fulfilled the requirement at the time of publication. 2, 3 Any antibody, which is subsequently shown in the published literature to be clinically validated can also be used in the testing. The use of controls in testing is similar between the 2 guidelines. For ER and PR testing, normal internal ducts and glands should show some ER and PR activity, which serves as a valuable internal control. If such normal elements are not present, the pathologist should be careful in calling the case ER or PR negative unless there is a positive on slide control and specimen handling considerations are met. [2] [3] [4] Requirements for initial testing validation and for appropriate quality assurance procedures are identical between the 2 publications. A separate document was published in 2011, which provides greater detail about the validation requirements. 8 Tests should be revalidated at least yearly and laboratories doing such testing should engage in mandatory proficiency testing and have laboratory inspections where these recommendations are monitored.
A critical element of both guideline documents is the review by the pathologist before reporting that the HER2 or ER or PR results are in keeping with those expected of the patient under study. Low-grade tumors are almost always ER and PR positive; high-grade tumors may be HER2 positive and about half of the HER2-positive tumors are also ER positive. By careful review of all the patient information, an appropriate interpretation can be rendered. 1, 2, 7 In 2011, there will be a review of the HER2 guideline by the ASCO/CAP panel and a minor revision of that document is likely. It is hoped that these guidelines will serve as a basis for the recommendations for all other predictive cancer factor testing so that all such important tests will have improved accuracy through standardizing testing parameters and monitoring pathologist and laboratory performance.
